Biolife Solutions INC Form 4 insider transactions

Troy Wichterman, Chief Financial Officer of Biolife Solutions Inc, reported multiple transactions in common stock on October 6, 2026.

Joydeep Goswami, a Director of Biolife Solutions Inc, reported a transaction in 53,156 shares of common stock on October 6, 2026.

Rachel Ellingson, a Director of Biolife Solutions Inc, reported a transaction in 57,995 shares of common stock on October 6, 2026.

Amy Duross, a Director of Biolife Solutions Inc, reported a transaction in 26,857 shares of common stock on October 6, 2026.

Catherine Coste, a Director of Biolife Solutions Inc, reported a transaction in 13,871 shares of common stock on October 6, 2026.

Greef Roderick De, Chief Executive Officer and a Director of Biolife Solutions Inc, reported multiple transactions in common stock on October 6, 2026.

Anthony Hunt, a Director of Biolife Solutions Inc, reported a transaction in 15,046 shares of common stock on October 6, 2026.

Timothy L. Moore, a Director of Biolife Solutions Inc, reported a transaction in 44,943 shares of common stock on October 6, 2026.

Aby J. Mathew, EVP & Chief Scientific Officer of Biolife Solutions Inc, reported multiple transactions in common stock on October 6, 2026.

Todd Berard, Chief Marketing Officer of Biolife Solutions Inc, reported multiple transactions in common stock on October 6, 2026.

Sean Werner, Chief Technology Officer of Biolife Solutions Inc, reported multiple transactions in common stock on October 6, 2026.

Repligen and BioLife provide supplemental disclosures regarding their merger, including details on executive compensation, ongoing litigation, and the upcoming BioLife stockholder meeting.

Todd Berard, Chief Marketing Officer of Biolife Solutions Inc, reported a transaction in 470 shares of common stock on September 18, 2026.

Aby J. Mathew, EVP & Chief Scientific Officer of Biolife Solutions Inc, reported a transaction in 564 shares of common stock on September 18, 2026.

Sean Werner, Chief Technology Officer of Biolife Solutions Inc, reported a transaction in 421 shares of common stock on September 18, 2026.

Greef Roderick De, President and CEO and a Director of Biolife Solutions Inc, reported a transaction in 2,775 shares of common stock on September 18, 2026.

Troy Wichterman, Chief Financial Officer of Biolife Solutions Inc, reported a transaction in 937 shares of common stock on September 18, 2026.

Todd Berard, Chief Marketing Officer of Biolife Solutions Inc, reported a transaction in 356 shares of common stock on September 8, 2026.

Aby J. Mathew, EVP & Chief Scientific Officer of Biolife Solutions Inc, reported a transaction in 627 shares of common stock on September 8, 2026.

Troy Wichterman, Chief Financial Officer of Biolife Solutions Inc, reported a transaction in 1,026 shares of common stock on September 8, 2026.

Repligen Corporation announced a definitive agreement to acquire BioLife Solutions, Inc. for a combination of cash and Repligen common stock, aiming to accelerate growth in the cell therapy market.

Sean Werner, Chief Technology Officer of Biolife Solutions Inc, reported a transaction in 275 shares of common stock on July 17, 2026.

Troy Wichterman, Chief Financial Officer of Biolife Solutions Inc, reported a transaction in 844 shares of common stock on July 7, 2026.

Aby J. Mathew, EVP & Chief Scientific Officer of Biolife Solutions Inc, reported a transaction in 516 shares of common stock on July 7, 2026.

Todd Berard, Chief Marketing Officer of Biolife Solutions Inc, reported a transaction in 293 shares of common stock on July 7, 2026.

CFO Troy Wichterman disposed of 1,026 shares of BioLife Solutions common stock to satisfy tax obligations related to restricted stock units.

Chief Marketing Officer Todd Berard reported the withholding of 356 shares of BioLife Solutions common stock to satisfy tax obligations.

EVP and Chief Scientific Officer Aby J. Mathew disposed of 627 shares of BioLife Solutions common stock to satisfy tax withholding obligations.

Major shareholder Casdin Partners Master Fund reduced its stake in BioLife Solutions by 1.2 million shares over three days.

Biolife Solutions EVP & Chief Scientific Officer, Mathew Aby J., reported a sale of 515 common shares on April 8, 2026, for $19.27 per share.